6. Merck & Co., Inc. (NYSE:MRK)
Number of Hedge Fund Holders as of Q4: 91
Bourgeon Capital’s Equity Stake: $14.71 Million
Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company dedicated to advancing healthcare through innovative medicines, vaccines, biologic therapies, and animal health products. With a strong focus on oncology, vaccines, infectious diseases, cardiometabolic disorders, immunology, and neuroscience, Merck has been at the forefront of medical advancements for over 130 years. The company prioritizes research and development to address current and future health challenges while fostering a diverse and inclusive workforce. Through its commitment to sustainability and responsible operations, Merck & Co., Inc. (NYSE:MRK) aims to create a healthier and safer world for people and communities worldwide.
Headquartered in Rahway, New Jersey, Merck is one of the largest pharmaceutical companies globally, operating as Merck Sharp & Dohme (MSD) outside the U.S. and Canada. Originally founded as the American arm of Germany’s Merck Group in 1891, the company has grown into a leader in the industry, ranking among the top five pharmaceutical firms by revenue. The company’s portfolio includes several blockbuster drugs and vaccines, such as Keytruda for cancer immunotherapy, Januvia for type 2 diabetes, and Gardasil for HPV prevention. Other significant products include treatments for infectious diseases, immunological disorders, and various vaccines, reinforcing the company’s role in improving global health.
Merck & Co., Inc. (NYSE:MRK) delivered a strong financial performance in the fourth quarter of 2024, reporting $15.62 billion in revenue—an increase of 6.8% compared to the same period the previous year. This growth highlights the company’s ability to expand its market presence and sustain solid business momentum. Additionally, Merck exceeded analyst expectations with earnings per share (EPS) of $1.72, surpassing projections of $1.67.
Merck & Co., Inc. (NYSE:MRK)’s consistent revenue growth and ability to outperform earnings estimates reinforce its position as a strong investment option. With a robust pipeline of innovative drugs and vaccines, the company continues to capitalize on high-demand healthcare solutions, making it a compelling stock for long-term growth and stability.
GreensKeeper Asset Management stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its Q3 2024 investor letter:
“Merck & Co., Inc. (NYSE:MRK) was our second-largest detractor this quarter, declining -8.3%. MRK’s leading HPV vaccine, GARDASIL 9, faced challenges internationally due to inventory buildup within its Chinese distributor, which is expected to reduce shipments for the remainder of 2024. Despite this short-term impact, the long-term outlook for GARDASIL 9 remains promising. Meanwhile, the company’s $27 billion Keytruda cancer juggernaut continues to grow at a healthy clip, powering earnings growth.”
